Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in R/R Aggressive B-NHL
NCT02910063Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2017
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of blinatumomab in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Amgen. Primary endpoint: Complete Metabolic Response at 12 weeks. Started Jan 2017; status: completed.
02
Drugs
blinatumomab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02910063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910063.